Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.

Bahar MA, Setiawan D, Hak E, Wilffert B.

Pharmacogenomics. 2017 May;18(7):701-739. doi: 10.2217/pgs-2017-0194. Epub 2017 May 8. Review.

PMID:
28480783
2.

Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Lu S, Nand RA, Yang JS, Chen G, Gross AS.

Eur J Clin Pharmacol. 2018 Mar;74(3):285-296. doi: 10.1007/s00228-017-2375-3. Epub 2017 Nov 27.

PMID:
29181698
3.

Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.

Chaudhry SR, Muhammad S, Eidens M, Klemm M, Khan D, Efferth T, Weisshaar MP.

Curr Drug Metab. 2014;15(7):711-8. Review.

PMID:
25429673
4.

Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.

Naranjo MG, Rodrigues-Soares F, Peñas-Lledó EM, Tarazona-Santos E, Fariñas H, Rodeiro I, Terán E, Grazina M, Moya GE, López-López M, Sarmiento AP, Calzadilla LR, Ramírez-Roa R, Ortiz-López R, Estévez-Carrizo FE, Sosa-Macías M, Barrantes R, LLerena A; CEIBA-Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF.

OMICS. 2018 Sep;22(9):575-588. doi: 10.1089/omi.2018.0114. Epub 2018 Sep 11.

PMID:
30183544
5.

Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.

Céspedes-Garro C, Rodrigues-Soares F, Jiménez-Arce G, Naranjo MG, Tarazona-Santos E, Fariñas H, Barrantes R, Llerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIBEF.

Rev Biol Trop. 2016 Sep;64(3):1067-76.

PMID:
29461783
6.

Applications of CYP450 testing in the clinical setting.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.

Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Review.

7.

How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?

Lagishetty CV, Deng J, Lesko LJ, Rogers H, Pacanowski M, Schmidt S.

J Clin Pharmacol. 2016 Oct;56(10):1221-31. doi: 10.1002/jcph.743. Epub 2016 Apr 26.

PMID:
27040602
8.

Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.

Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, Malmberg EM, McMillin GA.

J Clin Pharmacol. 2016 Dec;56(12):1570-1581. doi: 10.1002/jcph.771. Epub 2016 Jun 21.

PMID:
27198207
9.

Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels.

Conrado DJ, Rogers HL, Zineh I, Pacanowski MA.

Pharmacogenomics. 2013 Jan;14(2):215-23. doi: 10.2217/pgs.12.203. Review.

PMID:
23327581
10.

CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?

de Andrés F, Sosa-Macías M, Ramos BPL, Naranjo MG, LLerena A.

OMICS. 2017 Sep;21(9):509-519. doi: 10.1089/omi.2017.0101. Epub 2017 Sep 5.

PMID:
28873029
11.

Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.

McGrane IR, Loveland JG.

J Child Adolesc Psychopharmacol. 2016 May;26(4):395-9. doi: 10.1089/cap.2015.0180. Epub 2016 Feb 12.

PMID:
26871369
12.

Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.

Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K.

Int J Med Sci. 2015 Jan 1;12(1):78-82. doi: 10.7150/ijms.10263. eCollection 2015.

13.

How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping.

Verbeurgt P, Mamiya T, Oesterheld J.

Pharmacogenomics. 2014 Apr;15(5):655-65. doi: 10.2217/pgs.14.6.

PMID:
24798722
14.
15.

Clinical pharmacogenetics and potential application in personalized medicine.

Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W.

Curr Drug Metab. 2008 Oct;9(8):738-84. Review.

PMID:
18855611
16.

Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.

Tadje M.

Oncol Nurs Forum. 2014 Jul 1;41(4):443-4. doi: 10.1188/14.ONF.443-444.

PMID:
24969255
17.

Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Abdelhedi R, Bouayed NA, Alfadhli S, Abid L, Rebai A, Kharrat N.

J Genet. 2015 Dec;94(4):765-70. No abstract available.

18.

Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.

Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS, Brøsen K.

Eur J Clin Pharmacol. 2005 Aug;61(7):491-7. Epub 2005 Jul 16.

PMID:
16025294
19.

Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.

López-García MA, Feria-Romero IA, Serrano H, Rayo-Mares D, Fagiolino P, Vázquez M, Escamilla-Núñez C, Grijalva I, Escalante-Santiago D, Orozco-Suarez S.

Pharmacol Rep. 2017 Jun;69(3):504-511. doi: 10.1016/j.pharep.2017.01.007. Epub 2017 Jan 19.

PMID:
28343093
20.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29. Review.

Supplemental Content

Support Center